Navigation Links
Access to antiretrovirals unlikely to reduce HIV infection rates

A new study by Rebecca Baggaley, Neil Ferguson, and Geoff Garnett (of Imperial College London) suggests that the HIV epidemic in poor countries will not be controlled through antiretroviral drugs alone, even if universal access is achieved. As they demonstrate in an article in the open-access international medical journal PLoS Medicine, without additional prevention methods such as counseling patients and their communities about safe sex, access to drugs is likely to increase HIV/AIDS prevalence.

Sexual transmission of HIV is more likely if the HIV-positive partner has a higher viral load. Because antiretrovirals therapy (ART) slows AIDS progression and reduces viral load in infected individuals, the drugs not only improve the health and prolong the life of those who take them, but also make it less likely that they infect others. As a consequence, ART has been discussed not only as a treatment but also as a prevention tool in its own right.

To test this, Baggaley and colleagues used a model to predict and compare the impacts of alternative strategies of increasing ART access in resource-poor countries. Some of the strategies included the provision of diagnostic laboratories that could routinely measure CD4 counts and viral loads of HIV-infected individuals (only if this is done could people be treated before they develop overt symptoms). They also took into account different ways that people might change their sexual behavior if they get treatment (which might make them feel physically better and more likely to be sexually active) and counseling (which will hopefully increase safe sex practices).

They found that providing ART to all individuals with AIDS symptoms (i.e. those at the late stages of the disease) was likely to increase the prevalence of HIV infection, as these people live longer and become sexually active again. If ART is also provided to HIV-positive individuals at an earlier stage, i.e. when their immune system starts to get
'"/>

Source:Public Library of Science


Page: 1 2

Related biology news :

1. Open Access journals get impressive impact factors
2. Access to existing medical treatments could save more lives than spending to improve the treatments
3. Medical experts: US unlikely to have enough vaccines to stop avian flu
4. Ozone recovering, but unlikely to stabilize at pre-1980 levels, says study
5. Male circumcision reduces risk of HIV transmission from women to men
6. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
7. Use of PET can reduce, may eliminate more strenuous drug development trials with animals
8. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
9. Physiological effects of reduced gravity on bacteria
10. New strategies to reduce hospital-aquired infections
11. New miniaturised chip dramatically reduces time taken for DNA analysis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Access antiretrovirals unlikely reduce HIV infection rates

(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... enhanced the abilities of the molecules they are creating ... molecular complexes enter cancer cells and, when signaled, deliver ... new supermolecules have more units that will absorb light ... frequencies that can be included and excluded as signals ...
... DNA isn't just for storing genetic codes any more. ... into larger structures -- scientists have been using it ... even working mechanical devices. , Now Cornell University researchers ... could be used for drug delivery and as containers ...
... have become invaluable decision-making tools for public health ... epidemic of 2001, models can be useful in ... of an infection and they can allow the ... models make implicit assumptions that may systematically bias ...
Cached Biology News:Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 2Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 3Self-assembled DNA buckyballs for drug delivery 2Self-assembled DNA buckyballs for drug delivery 3Understanding biases in epidemic models important when making public health predictions 2
(Date:4/24/2015)... Seoul Semiconductor announced the expansion of ... the lighting market. In recent months, there ... in emerging markets such as Russia, South America, ... applications such as streetlight and area lighting, tunnel ... launched in 2005 the Acrich technology from Seoul ...
(Date:4/23/2015)... April 23, 2015 Athena San Diego, ... of executive women in San Diego’s technology and life ... Annual Pinnacle Awards at their Gala on April 30, ... Register now at http://athenasd.org/events/ , The Pinnacle ... Athena San Diego vision of fostering networking, risk taking ...
(Date:4/23/2015)... 23, 2015 /CNW/ - A new and innovative service ... North America,s largest packaging ... Silver in the "Sustainability, service" category of the ... "Competitor Comparison" is a service that scores clients, ... Global peers. This benchmarking process shows clients how ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 Six ... region on April 4-17 as part of the ... the fourth group of biotechnology startups to participate ... Nizhny Novgorod (UNN) and the University of Maryland ... ties between their respective universities in the biomedical ...
Breaking Biology Technology:Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4
... NeoStem, Inc.,(NYSE Alternext US: NBS), which is pioneering the pre-disease ... medical need,today announced that it has completed an above market ... $1.25 per unit with each unit,consisting of one share of ... stock at $1.75 per share. , ...
... SAN FRANCISCO, Calif., Dec. 3 Portola,Pharmaceuticals, a ... in cardiovascular disease, inflammatory disease,and cancer, today announced ... novel,compounds that inhibit spleen tyrosine kinase (Syk) and ... presented at the annual meeting of the,American Society ...
... , , QUEBEC CITY, ... AEZS ; TSX: AEZ), a global biopharmaceutical company ... has completed the transaction under the previously announced purchase ... ("CHRP") relating to AEterna Zentaris, rights to royalties on ...
Cached Biology Technology:NeoStem Completes $500,000 Private Placement With Strategic Investor 2NeoStem Completes $500,000 Private Placement With Strategic Investor 3Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 2Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 3AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3
Applications: Western blotting ...
...
... chemiluminescence efficiencies and the chemistry of light ... added benefit that they require simple triggering ... signal. This benefit has been exploited to ... These compounds can also be easily modified ...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
Biology Products: